文献速递前列腺癌

复发前列腺癌挽救性放疗联合激素治疗的系统综述与框架

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
PubMed 文献 · Eur Urol · 2017-07-14

该系统综述检索了截至2017年1月30日的随机临床试验,仅纳入两项符合标准的研究,评估挽救性放疗联合激素治疗的获益与危害。总体生存获益仅在一项试验中观察到,且限于随访≥10年、挽救性放疗前PSA≥0.7 ng/ml或更高Gleason分级或切缘阳性者;两项试验均显示高PSA患者获益。作者基于PSA、Gleason评分和切缘状态构建了激素治疗使用框架。

要点

  • 仅两项随机试验符合纳入标准,激素治疗获益因预后因素而异。
  • 总体生存获益限于随访≥10年、挽救性放疗前PSA≥0.7 ng/ml或高Gleason分级或切缘阳性者。
  • 两项试验均显示挽救性放疗前PSA较高的患者从激素治疗中获益。

核心结论

  • 并非所有患者都能从挽救性放疗联合激素治疗中获得有意义的获益。
  • 推荐使用激素治疗联合挽救性放疗时须考虑患者、肿瘤和治疗因素。
  • 关于激素治疗的最佳时长和类型以及利用预测生物标志物个体化使用激素治疗,一级证据存在知识空白。

研究设计与样本

  • 系统综述,于2017年2月15日在MEDLINE(通过PubMed)、EMBASE和ClinicalTrials.gov三个数据库检索1990年1月30日至2017年1月30日的人类随机临床试验。
  • 仅两项随机试验符合全部纳入标准。

主要发现

  • 总体生存获益仅在一项试验中发现,且限于随访延长至≥10年、挽救性放疗前PSA≥0.7 ng/ml或存在更高Gleason分级或切缘阳性时。
  • 两项试验均显示挽救性放疗前PSA较高的男性从激素治疗中获益。
  • 三个预后因素似乎可区分有意义的临床终点(如远处转移或生存)的改善:挽救性放疗前PSA、Gleason评分和切缘状态。
  • 两年比卡鲁胺单药治疗导致男性乳房发育发生率更高,在有利风险患者中生存有更差的趋势。
  • 6个月促黄体生成素释放激素激动剂治疗导致潮热和长期高血压发生率更高。

临床怎么用

  • 推荐使用激素治疗联合挽救性放疗时须考虑患者、肿瘤和治疗因素。
  • 作者基于挽救性放疗前PSA、Gleason评分和切缘状态构建了激素治疗联合挽救性放疗的使用框架。

局限性

  • 仅两项随机试验符合全部纳入标准。
  • 关于激素治疗的最佳时长和类型以及利用预测生物标志物个体化使用激素治疗,一级证据存在知识空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Salvage radiotherapy (SRT) is a standard of care for men who recur postprostatectomy, and recent randomized trials have assessed the benefit and toxicity of adding hormone therapy (HT) to SRT with differing results. OBJECTIVE: To perform a systematic review of randomized phase III trials of the use of SRT ± HT and generate a framework for the use of HT with SRT. EVIDENCE ACQUISITION: Systematic literature searches were conducted on February 15, 2017 in three databases (MEDLINE [via PubMed], EMBASE, and ClinicalTrials.gov) for human-only randomized clinical trials from January 30, 1990, through January 30, 2017. Only two randomized trials met all inclusion criteria. EVIDENCE SYNTHESIS: Overall survival benefits from HT were found in one trial, which was limited to when follow-up extended to ≥10 yr, pre-SRT prostate-specific antigen (PSA) ≥0.7 ng/ml, or when higher Gleason grade or positive margins were present. Both trials demonstrated a benefit from HT in men with higher pre-SRT PSAs. Three prognostic factors appeared to discriminate improvements in meaningful clinical endpoints (eg, distant metastasis or survival): pre-SRT PSA, Gleason score, and margin status. Two years of bicalutamide monotherapy resulted in higher rates of gynecomastia with a trend for worse survival when given in favorable risk patients, and 6 mo of luteinizing hormone-releasing hormone agonist therapy resulted in higher rates of hot flashes and long-term hypertension. CONCLUSIONS: Similar to the selective use of HT with radiotherapy in localized prostate cancer, not all patients appear to derive a meaningful benefit from HT with SRT. Patient, tumor, and treatment factors must be considered when recommending the use of HT with SRT. Knowledge gaps exist in the level 1 data regarding the optimal duration and type of HT, as well as the ability to use predictive biomarkers to personalize the use of HT with SRT. Important clinical trials (RADICALS and NRG GU-006) are aimed to answer these questions. PATIENT SUMMARY: In this report, we performed a systematic review of the literature to determine the benefit and harm of adding hormone therapy to salvage radiotherapy (SRT) for recurrent prostate cancer. We found that the benefit of hormone therapy varied by important prognostic factors, including pre-SRT prostate-specific antigen, Gleason grade, and surgical margin status. Our group then developed a framework on how best to utilize hormone therapy with SRT.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Spratt DE, Dess RT, Zumsteg ZS, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2017. PMID: 28716370. doi:10.1016/j.eururo.2017.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。